Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase

John Brognard1, You-Wei Zhang, Lorena A Puto

  • 1Signalling Networks in Cancer Group, Cancer Research UK, Paterson Institute for Cancer Research, The University of Manchester, Manchester, United Kingdom. jbrognard@picr.man.ac.uk

Cancer Research
|April 14, 2011
PubMed

Insights

Death-associated protein kinase 3 (DAPK3) mutations are linked to cancer. Loss-of-function mutations in this kinase impair cell cycle regulation and promote tumor growth and chemotherapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer kinome sequencing identifies potential driver mutations in protein kinases.
  • DAPK3 (ZIPK) is identified as a novel cancer-associated kinase with functional mutations.

Purpose of the Study:

  • To investigate the functional impact of DAPK3 mutations found in various tumors.
  • To determine the role of DAPK3 in cancer development and its potential as a tumor suppressor.

Main Methods:

  • Bioinformatic analysis to identify DAPK3 mutations.
  • Evaluation of kinase activity for nonsynonymous point mutations (T112M, D161N, P216S).
  • Phenotypic assays to assess DAPK3 function in cell cycle and survival.
  • Coexpression studies of wild-type (WT) and mutant DAPK3.
  • Reconstitution experiments in non-small cell lung cancer cells.

Main Results:

  • All three identified DAPK3 mutations (T112M, D161N, P216S) decrease or abolish kinase activity.
  • Cancer-associated DAPK3 mutations abrogate its function in regulating cell cycle and cell survival.
  • Mutant DAPK3 dominantly inhibits the function of WT DAPK3.
  • Restoring WT DAPK3 in lung cancer cells with a P216S mutation reduced cellular aggregation and increased chemotherapy sensitivity.

Conclusions:

  • DAPK3 functions as a tumor suppressor.
  • Loss-of-function mutations in DAPK3 promote cancer progression by increasing cell survival, proliferation, and cellular aggregation.
  • These mutations also contribute to increased resistance to chemotherapy, highlighting DAPK3 as a potential therapeutic target.

Related Concept Videos

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

We describe here a protocol to investigate cytotoxicity of pre-activated CD8+ T cells against cancer cells by detecting apoptotic cancer cells via real-time microscopy. This protocol can investigate mechanisms behind myeloid cell-induced T cell suppression and evaluate compounds aimed at replenishing T cells via blockade of immune suppressive myeloid...
23.4K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

This manuscript describes clinical protocols for two next-generation sequencing panels. One panel interrogates hematologic malignancies while the other panel targets genes commonly mutated in solid tumors. Molecular classification of driver mutations in human malignancies offers valuable prognostic and predictive...
25.0K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

We present a three-dimensional (3D) lung cancer model based on a biological collagen scaffold to study sensitivity towards non-small-cell-lung-cancer-(NSCLC)-targeted therapies. We demonstrate different read-out techniques to determine the proliferation index, apoptosis and epithelial-mesenchymal transition (EMT) status. Collected data are integrated into an in silico model for prediction of drug sensitivity.
10.6K
In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Tumor-initiating cells (TICs) may represent a viable therapeutic target for the treatment of ovarian cancer, a highly recurrent and fatal disease. We present a protocol for culture conditions that enrich for this highly tumorigenic population of...
14.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Emergence of genetic resistance against kinase inhibitor therapy poses significant challenge for effective cancer therapy. Identification and characterization of resistant mutations against a newly developed drug helps in better clinical management and next generation drug design. Here, we describe our protocol for in vitro screening and validation of resistant...
15.2K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.9K